NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sciwind Biosciences

Sciwind Biosciences

Private
HangzhouHealthcare & Life Scienceshttps://sciwindbio.com/

Last Round

IPO

Mar 23, 2026

Est. Valuation

$676M

Total Funding Raised

$336.48M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Sciwind Biosciences is a biopharmaceutical company that develops innovative therapies for the treatment of metabolic diseases, including obesity and type 2 diabetes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

GLP-1 receptor agonistweight loss drugGLP-1metabolic diseaseecnoglutidebiopharmaceuticaltype 2 diabetesoral peptideobesity treatmentdrug licensingamylin receptor agonistbiotechpharma pipelinedrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sciwind Biosciences Comparables

Compare Sciwind Biosciences with similar companies based on industry and business-model similarity.

Sciwind Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
QL Biopharm
87%
Verdiva Bio
84%
Kailera Therapeutics
83%

Sciwind Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOMar 23, 2026
Growth EquityJan 10, 2025
Series DDec 1, 2024
Series C ExtensionMar 1, 2023
Series C ExtensionDec 1, 2021
Series C
Oct 12, 2021

Key People

Founding team and executive leadership

Hai Pan

CEO

Executive Team

Sciwind Biosciences Investors

Notable investors and investment history

Sciwind Biosciences investors
InvestorRounds
Loyal Valley CapitalSeries C
IDG CapitalSeries C
Oriza HoldingsSeries B
Kaitai CapitalSeries B
China International Capital CorporationIPO
LYFE CapitalSeries C, Series B
Legend CapitalSeries C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 169% MoM.

  • Apr 17, 2026

    Grew 43% QoQ from 7 to 10 employees.

Sciwind Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sciwind Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sciwind Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range10
Year Founded2017
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.